Retinitis pigmentosa and ocular blood flow
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ferrari S, Di Iorio E, Barbaro V, Ponzin D, Sorrentino FS, Parmeggiani F: Retinitis pigmentosa: genes and disease mechanisms. Curr Genomics. 2011, 12: 238-249. 10.2174/138920211795860107.
Cellini M, Strobbe E, Gizzi C, Campos EC: ET-1 plasma levels and ocular blood flow in retinitis pigmentosa. Can J Physiol Pharmacol. 2010, 88: 630-635. 10.1139/Y10-036.
Grunwald JE, Maguire AM, Dupont J: Retinal hemodynamics in retinitis pigmentosa. Am J Ophthalmol. 1996, 122: 502-508.
Falsini B, Anselmi GM, Marangoni D, D'Esposito F, Fadda A, Di Renzo A, Campos EC, Riva CE: Subfoveal choroidal blood flow and central retinal function in retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2011, 52: 1064-1069. 10.1167/iovs.10-5964.
Chizzolini M, Galan A, Milan E, Sebastiani A, Costagliola C, Parmeggiani F: Good epidemiologic practice in retinitis pigmentosa: from phenotyping to biobanking. Curr Genomics. 2011, 12: 260-266. 10.2174/138920211795860071.
Heckenlively J: The frequency of posterior subcapsular cataract in the hereditary retinal degenerations. Am J Ophthalmol. 1982, 93: 733-738.
Sieving PA, Fishman GA: Refractive errors of retinitis pigmentosa patients. Br J Ophthalmol. 1978, 62: 163-167. 10.1136/bjo.62.3.163.
Fishman GA, Maggiano JM, Fishman M: Foveal lesions seen in retinitis pigmentosa. Arch Ophthalmol. 1977, 95: 1993-1996. 10.1001/archopht.1977.04450110087008.
Kajiwara K, Berson EL, Dryja TP: Digenic retinitis pigmentosa due to mutations at the unlinked peripherin/RDS and ROM1 loci. Science. 1994, 264: 1604-1608. 10.1126/science.8202715.
Mansergh FC, Millington-Ward S, Kennan A, Kiang AS, Humphries M, Farrar GJ, Humphries P, Kenna PF: Retinitis pigmentosa and progressive sensorineural hearing loss caused by a C12258A mutation in the mitochondrial MTTS2 gene. Am J Hum Genet. 1999, 64: 971-985. 10.1086/302344.
Marigo V: Programmed cell death in retinal degeneration: targeting apoptosis in photoreceptors as potential therapy for retinal degeneration. Cell Cycle. 2007, 6: 652-655. 10.4161/cc.6.6.4029.
Li ZY, Possin DE, Milam AH: Histopathology of bone spicule pigmentation in retinitis pigmentosa. Ophthalmology. 1995, 102: 805-816.
Flammer J, Mozaffarieh M, Bebie H: Basic Sciences in Ophthalmology: Physics and Chemistry. Heidelberg: Springer, in press
Komeima K, Rogers BS, Campochiaro PA: Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. J Cell Physiol. 2007, 213: 809-815. 10.1002/jcp.21152.
Wolf S, Pöstgens H, Bertram B, Schulte K, Teping C, Reim M: Hemodynamic findings in patients with retinitis pigmentosa. Klin Monbl Augenheilkd. 1991, 199: 325-329. 10.1055/s-2008-1046089.
Cellini M, Santiago L, Versura P, Caramazza R: Plasma levels of endothelin-1 in retinitis pigmentosa. Ophthalmologica. 2002, 216: 265-268. 10.1159/000063841.
Vingolo EM, Lupo S, Grenga PL, Salvatore S, Zinnamosca L, Cotesta D, Petramala L, Letizia C: Endothelin-1 plasma concentrations in patients with retinitis pigmentosa. Regul Pept. 2010, 160: 64-67. 10.1016/j.regpep.2009.12.006.
Ohguro H, Mashima Y, Nakazawa M: Low levels of plasma endothelin-1 in patients with retinitis pigmentosa. Clin Ophthalmol. 2010, 4: 569-573.
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988, 332: 411-415. 10.1038/332411a0.
Narayan S, Prasanna G, Krishnamoorthy RR, Zhang X, Yorio T: Endothelin-1 synthesis and secretion in human retinal pigment epithelial cells (ARPE-19): differential regulation by cholinergics and TNF-alpha. Invest Ophthalmol Vis Sci. 2003, 44: 4885-4894. 10.1167/iovs.03-0387.
Polak K, Petternel V, Luksch A, Krohn J, Findl O, Polska E, Schmetterer L: Effect of endothelin and BQ123 on ocular blood flow parameters in healthy subjects. Invest Ophthalmol Vis Sci. 2001, 42: 2949-2956.
Polak K, Luksch A, Frank B, Jandrasits K, Polska E, Schmetterer L: Regulation of human retinal blood flow by endothelin-1. Exp Eye Res. 2003, 76: 633-640. 10.1016/S0014-4835(02)00312-3.
Saner H, Würbel H, Mahler F, Flammer J, Gasser P: Microvasculatory evaluation of vasospastic syndromes. Adv Exp Med Biol. 1987, 220: 215-218.
Guthauser U, Flammer J, Mahler F: The relationship between digital and ocular vasospasm. Graefes Arch Clin Exp Ophthalmol. 1988, 226: 224-226. 10.1007/BF02181185.
Flammer J, Mozaffarieh M: Autoregulation, a balancing act between supply and demand. Can J Ophthalmol. 2008, 43: 317-321.
Flammer J: The concept of vascular dysregulation in glaucoma. Nitric Oxide and Endothelin in the Pathogenesis of Glaucoma. Edited by: Haefliger IO, Flammer J. 1998, Philadelphia: Lippincott-Raven, 14-21.
Mahler F, Saner H, Würbel H, Flammer J: Local cooling test for clinical capillaroscopy in Raynaud's phenomenon, unstable angina, and vasospastic visual disorders. Vasa. 1989, 18: 201-204.
Gherghel D, Orgül S, Gugleta K, Flammer J: Retrobulbar blood flow in glaucoma patients with nocturnal over-dipping in systemic blood pressure. Am J Ophthalmol. 2001, 132: 641-647. 10.1016/S0002-9394(01)01193-X.
Teuchner B, Orgül S, Ulmer H, Haufschild T, Flammer J: Reduced thirst in patients with a vasospastic syndrome. Acta Ophthalmol Scand. 2004, 82: 738-740. 10.1111/j.1600-0420.2004.00376.x.
Pechere-Bertschi A, Sunaric-Megevand G, Haefliger I, Panarello F, Maillard M, Burnier M: Renal sodium handling in patients with normal pressure glaucoma. Clin Sci. 2007, 112: 337-344. 10.1042/CS20060082.
Flammer J: Glaucoma. 2006, Bern: Hogrefe & Huber
Wunderlich K, Zimmerman C, Gutmann H, Teuchner B, Flammer J, Drewe J: Vasospastic persons exhibit differential expression of ABC-transport proteins. Mol Vis. 2003, 9: 756-761.
Pache M, Kräuchi K, Cajochen C, Wirz-Justice A, Dubler B, Flammer J, Kaiser HJ: Cold feet and prolonged sleep-onset latency in vasospastic syndrome. Lancet. 2001, 358: 125-126. 10.1016/S0140-6736(01)05344-2.
Gasser P, Meienberg O: Finger microcirculation in classical migraine. A video-microscopic study of nailfold capillaries. Eur Neurol. 1991, 31: 168-171. 10.1159/000116670.
Pache M, Ochs J, Genth E, Mierau R, Kube T, Flammer J: Increased plasma endothelin-1 levels in fibromyalgia syndrome. Rheumatology. 2003, 42: 493-494. 10.1093/rheumatology/keg131.
Mozaffarieh M, Fontana Gasio P, Schötzau A, Orgül S, Flammer J, Kräuchi K: Thermal discomfort with cold extremities in relation to age, gender, and body mass index in a random sample of a Swiss urban population. Popul Health Metr. 2010, 8: 17-10.1186/1478-7954-8-17.
Kavroulaki D, Gugleta K, Kochkorov A, Katamay R, Flammer J, Orgül S: Relation of body mass index and blood pressure to subjective and objective acral temperature. Klin Monbl Augenheilkd. 2009, 226: 328-331. 10.1055/s-0028-1109290.
Gasser P, Stümpfig D, Schötzau A, Ackermann-Liebrich U, Flammer J: Body mass index in glaucoma. J Glaucoma. 1999, 8: 8-11.
Emre M, Orgül S, Gugleta K, Flammer J: Ocular blood flow alteration in glaucoma is related to systemic vascular dysregulation. Br J Ophthalmol. 2004, 88: 662-666. 10.1136/bjo.2003.032110.
Gugleta K, Zawinka C, Rickenbacher I, Kochkorov A, Katamay R, Flammer J, Orgul S: Analysis of retinal vasodilation after flicker light stimulation in relation to vasospastic propensity. Invest Ophthalmol Vis Sci. 2006, 47: 4034-4041. 10.1167/iovs.06-0351.
Mozaffarieh M, Schoetzau A, Sauter M, Grieshaber M, Orgül S, Golubnitschaja O, Flammer J: Comet assay analysis of single-stranded DNA breaks in circulating leukocytes of glaucoma patients. Mol Vis. 2008, 14: 1584-1588.
Gugleta K, Orgül S, Stümpfig D, Dubler B, Flammer J: Fludrocortisone in the treatment of systemic hypotension in primary open-angle glaucoma patients. Int Ophthalmol. 1999, 23: 25-30. 10.1023/A:1006434231844.
Gaspar AZ, Gasser P, Flammer J: The influence of magnesium on visual field and peripheral vasospasm in glaucoma. Ophthalmologica. 1995, 209: 11-13. 10.1159/000310566.
Strenn K, Matulla B, Wolzt M, Findl O, Bekes MC, Lamsfuss U, Graselli U, Rainer G, Menapace R, Eichler HG, Schmetterer L: Reversal of endothelin-1-induced ocular hemodynamic effects by low-dose nifedipine in humans. Clin Pharmacol Ther. 1998, 63: 54-63. 10.1016/S0009-9236(98)90121-7.
Nyby MD, Hori MT, Ormsby B, Gabrielian A, Tuck ML: Eicosapentaenoic acid inhibits Ca2+ mobilization and PKC activity in vascular smooth muscle cells. Am J Hypertens. 2003, 16: 708-714. 10.1016/S0895-7061(03)00980-4.
Shirao S, Fujisawa H, Kudo A, Kurokawa T, Yoneda H, Kunitsugu I, Ogasawara K, Soma M, Kobayashi S, Ogawa A, Suzuki M: Inhibitory effects of eicosapentaenoic acid on chronic cerebral vasospasm after subarachnoid hemorrhage: possible involvement of a sphingosylphosphorylcholine-rho-kinase pathway. Cerebrovasc Dis. 2008, 26: 30-37.
Nakazawa M, Ohguro H, Takeuchi K, Miyagawa Y, Ito T, Metoki T: Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial. Ophthalmologica. 2011, 225: 120-126. 10.1159/000320500.
Liang SY, Lee LR: Retinitis pigmentosa associated with hypomagnesaemia. Clin Experiment Ophthalmol. 2010, 38: 645-647. 10.1111/j.1442-9071.2010.02314.x.
Meyer P, Lang MG, Flammer J, Lüscher TF: Effects of calcium channel blockers on the response to endothelin-1, bradykinin and sodium nitroprusside in porcine ciliary arteries. Exp Eye Res. 1995, 60: 505-510. 10.1016/S0014-4835(05)80065-X.
Dettmann ES, Lüscher TF, Flammer J, Haefliger IO: Modulation of endothelin-1-induced contractions by magnesium/calcium in porcine ciliary arteries. Graefes Arch Clin Exp Ophthalmol. 1998, 236: 47-51. 10.1007/s004170050041.
Berson EL, Rosner B, Sandberg MA, Weigel-Difranco C, Willett WC: ω-3 intake and visual acuity in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol. 2012, 130: 707-711.
Komeima K, Rogers BS, Lu L, Campochiaro PA: Antioxidants reduce cone cell death in a model of retinitis pigmentosa. Proc Natl Acad Sci USA. 2006, 103: 11300-11305. 10.1073/pnas.0604056103.
Golubnitschaja O, Costigliola V: EPMA: General Report & Recommendations in Predictive, Preventive and Personalised Medicine 2012: White Paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012, 3: 14-10.1186/1878-5085-3-14.